target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id GPR35,102,Q9HC97,Human,kynurenic acid,2918,,3845,OC(=O)c1cc(=O)c2c([nH]1)cccc2,"InChI=1S/C10H7NO3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5H,(H,11,12)(H,13,14)",HCZHHEIFKROPDY-UHFFFAOYSA-N,Agonist,Agonist,,yes,,,pEC50,4.41,,3.9,,,,,=,,,,16754668|23396314, GPR35,102,Q9ES90,Mouse,kynurenic acid,2918,,3845,OC(=O)c1cc(=O)c2c([nH]1)cccc2,"InChI=1S/C10H7NO3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5H,(H,11,12)(H,13,14)",HCZHHEIFKROPDY-UHFFFAOYSA-N,Agonist,Agonist,,yes,,,pEC50,,4.96,,,,,,,,,,16754668, GPR35,102,Q33BM1,Rat,kynurenic acid,2918,,3845,OC(=O)c1cc(=O)c2c([nH]1)cccc2,"InChI=1S/C10H7NO3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5H,(H,11,12)(H,13,14)",HCZHHEIFKROPDY-UHFFFAOYSA-N,Agonist,Agonist,,yes,,,pEC50,,5.15,,,,,,,,,,16754668, GPR35,102,Q9HC97,Human,zaprinast,2919,,135399235,CCCOc1ccccc1c1nc(=O)c2c(n1)[nH][nH]n2,"InChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)",REZGGXNDEMKIQB-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,6.1,,,,,,,,,,16934253, GPR35,102,Q33BM1,Rat,zaprinast,2919,,135399235,CCCOc1ccccc1c1nc(=O)c2c(n1)[nH][nH]n2,"InChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)",REZGGXNDEMKIQB-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,7.8,,,,,,,,,,16934253, GPR35,102,Q9HC97,Human,pamoic acid,2920,,8546,OC(=O)c1cc2ccccc2c(c1O)Cc1c(O)c(cc2c1cccc2)C(=O)O,"InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)",WLJNZVDCPSBLRP-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,7.29,,,,,,,,,,20919992, GPR35,102,Q33BM1,Rat,pamoic acid,2920,,8546,OC(=O)c1cc2ccccc2c(c1O)Cc1c(O)c(cc2c1cccc2)C(=O)O,"InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)",WLJNZVDCPSBLRP-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,5.0,,3.0,,,,,,,,,20919992, GPR35,102,Q9HC97,Human,2-oleoyl-LPA,2936,,56947016,CCCCCCCC/C=C\CCCCCCCC(=O)OC(COP(=O)(O)O)CO,"InChI=1S/C21H41O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)28-20(18-22)19-27-29(24,25)26/h9-10,20,22H,2-8,11-19H2,1H3,(H2,24,25,26)/b10-9-",ZOOLJLSXNRZLDH-KTKRTIGZSA-N,Agonist,Agonist,,yes,,,pEC50,7.52,,7.3,,,,,=,,,,20361937, GPR35,102,Q9HC97,Human,bumetanide,4837,,2471,CCCCNc1cc(cc(c1Oc1ccccc1)S(=O)(=O)N)C(=O)O,"InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)",MAEIEVLCKWDQJH-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,5.54,,5.0,,,,,=,,,,22236570, GPR35,102,Q9HC97,Human,furosemide,4839,,3440,OC(=O)c1cc(c(cc1NCc1ccco1)Cl)S(=O)(=O)N,"InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)",ZZUFCTLCJUWOSV-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,5.63,,5.21,,,,,=,,,,22236570, GPR35,102,Q9HC97,Human,CXCL17,6479,Human,,,,,Agonist,Agonist,,,,,,,,,,,,,=,As assessed by ability to induce GRR35-dependent calcium flux.,,,25411203, GPR35,102,Q9HC97,Human,CID2745687,9741,,2745687,COC(=O)c1cnn(c1C=NNC(=S)NC(C)(C)C)c1ccc(cc1F)F,"InChI=1S/C17H19F2N5O2S/c1-17(2,3)22-16(27)23-20-9-14-11(15(25)26-4)8-21-24(14)13-6-5-10(18)7-12(13)19/h5-9H,1-4H3,(H2,22,23,27)",CYNLZIBKERMMOA-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pIC50,,6.7,,IC50,,200.0,,=,Antagonism of zaprinast-mediated activation of GPR35 in a β-arrestin assay.,,,23888932, GPR35,102,Q9HC97,Human,CID2745687,9741,,2745687,COC(=O)c1cnn(c1C=NNC(=S)NC(C)(C)C)c1ccc(cc1F)F,"InChI=1S/C17H19F2N5O2S/c1-17(2,3)22-16(27)23-20-9-14-11(15(25)26-4)8-21-24(14)13-6-5-10(18)7-12(13)19/h5-9H,1-4H3,(H2,22,23,27)",CYNLZIBKERMMOA-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pIC50,,4.98,,IC50,,10400.0,,=,Antagonism of zaprinast-mediated activation of GPR35 in a dynamic mass redistribution assay.,,,23888932, GPR35,102,Q9HC97,Human,CID2745687,9741,,2745687,COC(=O)c1cnn(c1C=NNC(=S)NC(C)(C)C)c1ccc(cc1F)F,"InChI=1S/C17H19F2N5O2S/c1-17(2,3)22-16(27)23-20-9-14-11(15(25)26-4)8-21-24(14)13-6-5-10(18)7-12(13)19/h5-9H,1-4H3,(H2,22,23,27)",CYNLZIBKERMMOA-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pKi,,7.89,,Ki,,12.8,,=,Antagonism of the GPR35 response to 1 μM pamoic acid in a βarrestin2-GFP trafficking assay.,,,20826425, GPR35,102,Q9HC97,Human,CID2745687,9741,,2745687,COC(=O)c1cnn(c1C=NNC(=S)NC(C)(C)C)c1ccc(cc1F)F,"InChI=1S/C17H19F2N5O2S/c1-17(2,3)22-16(27)23-20-9-14-11(15(25)26-4)8-21-24(14)13-6-5-10(18)7-12(13)19/h5-9H,1-4H3,(H2,22,23,27)",CYNLZIBKERMMOA-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pKi,,7.37,,Ki,,42.2,,=,In a competition radiologand binding assay membranes preapred from CHO cells recombinantly expressing human GPR35.,,,23888932, GPR35,102,Q9HC97,Human,compound 83 [PMID: 23888932],9742,,73294508,COc1cc(F)c(c(c1)F)C(=O)Nc1cc(Br)cc2c1oc(cc2=O)C(=O)O,"InChI=1S/C18H10BrF2NO6/c1-27-8-4-10(20)15(11(21)5-8)17(24)22-12-3-7(19)2-9-13(23)6-14(18(25)26)28-16(9)12/h2-6H,1H3,(H,22,24)(H,25,26)",GDUANFXPOZTYKS-UHFFFAOYSA-N,Agonist,Agonist,,,,,pKi,,9.23,,Ki,,0.59,,=,In a radioligand competition binding assay using membranes prepared from CHO cells recombinantly expressing human GPR35.,,,23888932, GPR35,102,Q9HC97,Human,lodoxamide,9743,,44564,N#Cc1cc(NC(=O)C(=O)O)c(c(c1)NC(=O)C(=O)O)Cl,"InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)",RVGLGHVJXCETIO-UHFFFAOYSA-N,Agonist,Agonist,,,,,pEC50,,9.0,,EC50,,1.0,,=,In an AP-TGF-α shedding assay using GPR35 expressing HEK293 cells.,,,29068046,